Nirsevimab shows promise for long-term RSV protection

30th July 2020 Uncategorised 0

The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose

More: Nirsevimab shows promise for long-term RSV protection
Source: News